BAYZF - J&J beats in Q2 as pharma segment outperforms
2024-07-17 07:16:11 ET
More on Johnson & Johnson
- Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality
- Johnson & Johnson: Remaining A Buy Despite Remaining Risks
- Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
- Johnson & Johnson declares $1.24 dividend
- Johnson & Johnson Non-GAAP EPS of $2.82 beats by $0.12, revenue of $22.4B beats by $60M